Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175663 | 0.60 | ALDH1A1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL27553500 | 0.58 | ALDH1A1 (0.33) | ALDH1A1LMNAPKM | |
| SCHEMBL7614901 | 0.56 | PKM (0.39) | KDM4EALDH1A1KMT2ALMNAPKM | |
| SCHEMBL4914776 | 0.55 | LMNA (0.37) | KDM4EALDH1A1KMT2ALMNAPKM | |
| SCHEMBL1123731 | 0.52 | PKM (0.35) | KDM4EALDH1A1KMT2ALMNAPKM | |
| SCHEMBL5004603 | 0.51 | KDM4E (0.52) | KDM4EKMT2AMAPT | |
| SCHEMBL12755231 | 0.49 | ALDH1A1 (0.37) | KDM4EALDH1A1KMT2ALMNAPKM | |
| SCHEMBL9419448 | 0.48 | — | — | |
| SCHEMBL387691 | 0.45 | — | — | |
| SCHEMBL15407811 | 0.44 | TSHR (0.41) | KDM4EALDH1A1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | claimed |
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | TYR, MITF, MAOA | KDM4E 1950/4885ALDH1A1 69/4885KMT2A 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.